ZA936492B - Compounds useful as hypoglycemic agents and for treating Alzheimer's disease. - Google Patents

Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.

Info

Publication number
ZA936492B
ZA936492B ZA936492A ZA936492A ZA936492B ZA 936492 B ZA936492 B ZA 936492B ZA 936492 A ZA936492 A ZA 936492A ZA 936492 A ZA936492 A ZA 936492A ZA 936492 B ZA936492 B ZA 936492B
Authority
ZA
South Africa
Prior art keywords
disease
compounds useful
treating alzheimer
hypoglycemic agents
hypoglycemic
Prior art date
Application number
ZA936492A
Other languages
English (en)
Inventor
Juliana Bue-Valleskey
Charles David Jones
Walter Norman Shaw
David Charls Hunden
Jill Ann Panetta
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA936492B publication Critical patent/ZA936492B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65H—HANDLING THIN OR FILAMENTARY MATERIAL, e.g. SHEETS, WEBS, CABLES
    • B65H2511/00—Dimensions; Position; Numbers; Identification; Occurrences
    • B65H2511/50—Occurence
    • B65H2511/51—Presence
    • B65H2511/512—Marks, e.g. invisible to the human eye; Patterns

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA936492A 1992-09-10 1993-09-02 Compounds useful as hypoglycemic agents and for treating Alzheimer's disease. ZA936492B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94335392A 1992-09-10 1992-09-10

Publications (1)

Publication Number Publication Date
ZA936492B true ZA936492B (en) 1995-03-02

Family

ID=25479507

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA936492A ZA936492B (en) 1992-09-10 1993-09-02 Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.

Country Status (20)

Country Link
US (3) US5523314A (member.php)
EP (2) EP0915090A1 (member.php)
JP (1) JPH06192091A (member.php)
KR (1) KR940006590A (member.php)
CN (1) CN1091006A (member.php)
AU (1) AU676843B2 (member.php)
CA (1) CA2105598A1 (member.php)
CZ (1) CZ181493A3 (member.php)
FI (1) FI933946L (member.php)
HU (1) HUT70184A (member.php)
IL (1) IL106877A (member.php)
MX (1) MX9305444A (member.php)
MY (1) MY131443A (member.php)
NO (2) NO933198L (member.php)
NZ (1) NZ248573A (member.php)
PL (1) PL300335A1 (member.php)
RU (1) RU2131251C1 (member.php)
TW (1) TW274546B (member.php)
YU (1) YU59593A (member.php)
ZA (1) ZA936492B (member.php)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119252A2 (en) * 2004-05-26 2005-12-15 Arena Pharmaceuticals, Inc. Modulators of gpr35 for the treatment of metabolic-related disorders
NZ248573A (en) * 1992-09-10 1996-02-27 Lilly Co Eli 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
ATE238297T1 (de) * 1994-10-20 2003-05-15 Nippon Chemiphar Co Chinolinderivat
US5563277A (en) * 1994-12-21 1996-10-08 Eli Lilly And Company Process for preparing benzyl-substituted rhodanine derivatives
IL117208A0 (en) * 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
US5783434A (en) * 1995-06-06 1998-07-21 Tung; Jay S. Cathepsin and methods and compositions for inhibition thereof
US5849711A (en) * 1995-06-06 1998-12-15 Athena Neurosciences, Inc. Cathepsin and methods and compositions for inhibition thereof
CA2221684A1 (en) * 1995-06-06 1996-12-12 Athena Neurosciences, Inc. Novel cathepsin and methods and compositions for inhibition thereof
JPH09176162A (ja) * 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
AU726664B2 (en) * 1996-07-11 2000-11-16 Warner-Lambert Company Method for treating and preventing neurodegenerative disorders by administering a thiazolidinone
US6063799A (en) * 1996-09-03 2000-05-16 Eli Lilly And Company Alternate crystal form of Tazofelone
US6005142A (en) 1996-09-03 1999-12-21 Eli Lilly And Company Process for preparing benzyl-substituted rhodanine derivatives
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
JP2001514663A (ja) 1997-03-12 2001-09-11 エスモンド，ロバート ダブリュー． アルツハイマー病を処置または予防するための方法
AU7639598A (en) 1997-05-29 1998-12-30 H. Lundbeck A/S Treatment of schizophrenia and psychosis
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
WO1999055894A1 (en) 1998-04-29 1999-11-04 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
AU6330999A (en) * 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
US6673816B1 (en) 1998-09-30 2004-01-06 Angelika Esswein Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders
AU6229699A (en) * 1998-10-26 2000-05-15 Sumitomo Pharmaceuticals Company, Limited Beta-amyloid formation inhibitors
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6127394A (en) * 1999-03-08 2000-10-03 The University Of Mississippi 1,2-Dithiolane derivatives
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
TR200103561T2 (tr) * 1999-06-10 2002-04-22 Warner Lambert Company Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları
WO2000076987A1 (en) * 1999-06-10 2000-12-21 Warner-Lambert Company Rhodanine derivatives for use in a method of inhibiting amyloid protein aggregation and imaging amyloid deposits
AU6062900A (en) * 1999-07-01 2001-01-22 Geron Corporation Substituted indole compounds and their use for the treatment of cancer
EP1593677A3 (en) * 1999-08-31 2006-01-04 Incyte San Diego Incorporated Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
AU6949900A (en) 1999-08-31 2001-03-26 Maxia Pharmaceuticals, Inc. Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
US20070060606A1 (en) * 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
US6706766B2 (en) * 1999-12-13 2004-03-16 President And Fellows Of Harvard College Small molecules used to increase cell death
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
ATE310733T1 (de) * 2000-04-21 2005-12-15 Pfizer Prod Inc Thyroid-rezeptorliganden
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
JP2003531883A (ja) * 2000-05-04 2003-10-28 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アミノインダン誘導体を用いたアミロイドタンパク質の凝集を抑制する方法およびアミロイド沈着部画像化の方法
GB0021421D0 (en) * 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
BR0207846A (pt) 2001-03-07 2005-09-13 Incyte San Diego Inc Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
CA2473156A1 (en) * 2001-03-08 2002-09-19 Incyte San Diego, Inc. Rxr activating molecules
CA2340824A1 (en) * 2001-03-14 2002-09-14 Ibm Canada Limited-Ibm Canada Limitee Method and system for application behavior analysis
JP2005500379A (ja) * 2001-08-17 2005-01-06 インサイト サンディエゴ インコーポレーテッド 異脂肪血症および高コレステロール血症を治療するオキシム誘導体
US7071218B2 (en) * 2001-11-15 2006-07-04 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
HRP20041207A2 (en) * 2002-07-10 2005-04-30 Applied Research Systems Ars Holding N.V. Azolidinone-vinyl fused-benzene derivatives
US7005523B2 (en) * 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
WO2004043955A1 (en) * 2002-11-13 2004-05-27 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
SI1567112T1 (sl) 2002-11-22 2009-02-28 Smithkline Beecham Corp Thiazolidin-4-oni za inhibiranje proteinov hyak3
WO2004066952A2 (en) * 2003-01-29 2004-08-12 Incyte Corporation Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
WO2004087053A2 (en) 2003-03-25 2004-10-14 Syrrx, Inc. Dipeptidyl peptidase inhibitors
EP1643993A2 (en) * 2003-04-18 2006-04-12 Incyte San Diego Incorporated Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
US20060106077A1 (en) * 2003-07-18 2006-05-18 Pintex Pharmaceuticals, Inc. Pin1-Modulating compounds and methods of use thereof
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CN102134231B (zh) 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
DE102005022182A1 (de) * 2005-05-09 2006-11-16 Combinature Biopharm Ag Modulatoren der PDZ-Domäne
PE20070083A1 (es) * 2005-06-08 2007-01-27 Smithkline Beecham Corp (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
PE20070522A1 (es) 2005-09-14 2007-07-11 Takeda Pharmaceutical 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo como inhibidor de dipeptidil peptidasa y composiciones farmaceuticas que lo contienen
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
KR100814109B1 (ko) * 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
WO2007087684A1 (en) 2006-02-03 2007-08-09 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
DE112007001030T5 (de) 2006-04-28 2009-02-26 Kagoshima University Amyloid-ß-Fibrillogenese-inhibierendes Peptid
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
PT2650380E (pt) 2007-07-31 2016-01-14 Accera Inc Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida
JP2011502998A (ja) * 2007-11-01 2011-01-27 ザ ユーエイビー リサーチ ファウンデイション ウイルス感染の治療および予防
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
WO2010019550A2 (en) * 2008-08-12 2010-02-18 Shiraz Pharmaceuticals, Inc. Method of identifying disease risk factors
CA2759187A1 (en) * 2009-04-03 2010-10-07 Medisyn Technologies, Inc. Compositions for treatment of alzheimer's disease
KR101858097B1 (ko) * 2009-12-23 2018-05-15 자스코 파머수티컬스, 엘엘씨 아미노피리미딘 키나제 억제제
EP2399612B1 (en) * 2009-12-25 2018-02-21 Canon Kabushiki Kaisha Composition for labeling tissues of central nervous system, method for labeling tissues of central nervous system, and screening method using the composition for labeling tissues of central nervous system
CN102558088A (zh) * 2010-12-31 2012-07-11 中国科学院上海药物研究所 联苯亚甲基-2-硫代-4-噻唑酮类化合物及其制备方法和用途
PH12013501450A1 (en) 2011-01-10 2013-08-28 Takeda Pharmaceuticals Co Methods and drug products for treating alzheimer`s diseases
US9056862B2 (en) 2011-05-10 2015-06-16 National University Corporation Kobe University Thioxothiazolidine derivative having Ras function inhibitory effect
WO2013183718A1 (ja) * 2012-06-06 2013-12-12 国立大学法人京都大学 スクリーニング方法、タンパク質の不安定性及び／又は安定性を誘導する物質、及び、タンパク質の活性評価
US9623015B2 (en) 2012-11-05 2017-04-18 Commissariat À L'energie Atomique Et Aux Energies Alternatives (Cea) Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a STAT5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
WO2016077793A1 (en) * 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment
CN104557767B (zh) * 2015-01-14 2016-06-29 成都中医药大学 罗丹宁手性环己烷螺环化合物及其制备方法与用途
CN106008494B (zh) * 2016-05-31 2019-08-27 广东工业大学 一种含4-氧代-2-硫代噻唑烷基衍生物及其制备方法与应用
KR102491260B1 (ko) * 2019-12-26 2023-01-27 연세대학교 산학협력단 피롤리딘 유도체 및 이를 포함하는 베타-아밀로이드 또는 타우 단백질 관련 질병의 예방 또는 치료용 약학 조성물

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU173773A (member.php) *
DE1038050B (de) * 1955-11-17 1958-09-04 Farmaceutici Italia S A Soc Verfahren zur Herstellung von 5-(3', 4'-Dioxybenzyliden)-Derivaten heterocyclischer Verbindungen
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
AU6610081A (en) * 1980-01-24 1981-07-30 Senju Pharmaceutical Co., Ltd. Thiazolidine derivatives
JPS5728074A (en) * 1980-07-28 1982-02-15 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation, and inhibitor for aldose reducing enzyme consisting essentially of it
JPS5740478A (en) * 1980-08-22 1982-03-06 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative
US4636516A (en) * 1981-02-19 1987-01-13 Yamanouchi Pharmaceutical Co., Ltd. 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
US4617312A (en) * 1983-01-17 1986-10-14 Pfizer Inc. Aldose reductase inhibiting 5-(2-alkoxyphenyl) thiazolidinediones
US4552891A (en) * 1983-09-13 1985-11-12 Eli Lilly And Company Benzothiophene derivatives
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4703052A (en) * 1985-05-21 1987-10-27 Pfizer Inc. Hypoglycemic thiazolidinediones
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
JPS6212776A (ja) * 1985-07-10 1987-01-21 Taiho Yakuhin Kogyo Kk ロ−ダニン誘導体
US5356917A (en) * 1985-08-09 1994-10-18 Eli Lilly And Company Aryl-substituted rhodanine derivatives
CA1285572C (en) * 1985-08-09 1991-07-02 Jill Ann Panetta Di-t-butylphenol compounds
CA1325222C (en) * 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
DK4487A (da) * 1986-01-07 1987-07-08 Yamanouchi Pharma Co Ltd Heterocycliske forbindelser og farmaceutiske praeparater indeholdende disse
US4971996A (en) * 1987-03-11 1990-11-20 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds which are useful as tyrosine kinase inhibitors
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
ES2052675T3 (es) * 1987-11-20 1994-07-16 Hoechst Roussel Pharma 3-(4-piperazinil-sustituido en 1)butil)-4-tiazolidinonas, un procedimiento para su preparacion y su uso como medicamentos.
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
IE940525L (en) * 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
US5208250A (en) * 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
US4863923A (en) * 1988-07-01 1989-09-05 Eli Lilly And Company Method of inhibiting superoxide release
CA2013599C (en) * 1989-04-07 1999-11-16 Jill A. Panetta Aryl-substituted rhodanine derivatives
JPH02300119A (ja) * 1989-05-11 1990-12-12 Kanegafuchi Chem Ind Co Ltd 過酸化脂質生成抑制剤
DE69024843T2 (de) * 1989-05-19 1996-05-30 Nisshin Flour Milling Co., Ltd., Tokio/Tokyo Rhodanin-Derivate und pharmazeutische Zusammensetzungen
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US4997948A (en) * 1989-10-27 1991-03-05 American Home Products 5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
ZA9010041B (en) * 1989-12-21 1992-08-26 Lilly Co Eli Compounds for treating inflammatory bowel disease
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
DE4027038A1 (de) * 1990-08-27 1992-03-05 Wella Ag 3-amino-5-benzyliden-2-thioxo-thiazolidin-4- one, verfahren zu deren herstellung und diese enthaltendes kosmetisches mittel
EP0770644A1 (en) * 1991-02-15 1997-05-02 Mitsui Toatsu Chemicals, Incorporated Transparent impact-resistant molded articles
US5158966A (en) * 1991-02-22 1992-10-27 The University Of Colorado Foundation, Inc. Method of treating type i diabetes
US5143929A (en) * 1991-05-09 1992-09-01 Warner-Lambert Company 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
US5320770A (en) * 1992-04-27 1994-06-14 Dow Corning Corporation Electrorheological (ER) fluid based on amino acid containing metal polyoxo-salts
AU679675B2 (en) * 1992-05-11 1997-07-10 Bayer Corporation Methods for detecting beta amyloid precursor protein processing enzymes
US5236941A (en) * 1992-06-30 1993-08-17 American Home Products Corporation 5-(2-hydroxy-1-arylethylidene)- and 5-(2-oxo-1-arylethylidene)-2,4-thiazolidinediones and derivatives thereof
NZ248573A (en) * 1992-09-10 1996-02-27 Lilly Co Eli 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions
US5506745A (en) * 1994-08-05 1996-04-09 Xerox Corporation Hollow conformable charge roll

Also Published As

Publication number Publication date
NO981911L (no) 1994-03-11
EP0587377A2 (en) 1994-03-16
FI933946A0 (fi) 1993-09-09
NO933198L (no) 1994-03-11
EP0915090A1 (en) 1999-05-12
KR940006590A (ko) 1994-04-25
FI933946A7 (fi) 1994-03-11
JPH06192091A (ja) 1994-07-12
RU2131251C1 (ru) 1999-06-10
PL300335A1 (en) 1994-03-21
TW274546B (member.php) 1996-04-21
AU676843B2 (en) 1997-03-27
CZ181493A3 (en) 1994-03-16
US5661168A (en) 1997-08-26
AU4621893A (en) 1994-03-17
MX9305444A (es) 1994-05-31
MY131443A (en) 2007-08-30
EP0587377A3 (en) 1994-09-21
HU9302551D0 (en) 1993-11-29
US5523314A (en) 1996-06-04
YU59593A (sh) 1997-01-08
IL106877A (en) 1998-03-10
FI933946L (fi) 1994-03-11
NO933198D0 (no) 1993-09-08
NZ248573A (en) 1996-02-27
US5716975A (en) 1998-02-10
IL106877A0 (en) 1993-12-28
CN1091006A (zh) 1994-08-24
CA2105598A1 (en) 1994-03-11
HUT70184A (en) 1995-09-28
NO981911D0 (no) 1998-04-28

Similar Documents

Publication Publication Date Title
ZA936492B (en) Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
EP1043991A4 (en) TREATMENT OF ALZHEIMER DISEASE
EP0951293A4 (en) METHOD FOR TREATING ALZHEIMER DISEASE
ZA9410095B (en) Methods of inhibiting Alzheimer's Disease
EP0613560A4 (en) METHOD FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE.
AU3279395A (en) Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
ZA989365B (en) Preparation for treating alzheimer's disease
AU7556994A (en) Methods for the diagnosis of alzheimer's disease
IL114466A0 (en) A method for treating and preventing alzheimer's disease
PH31643A (en) 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease.
ITMI931181A1 (it) Procedimento per l'ulteriore trattamento di salcicce
AU1405899A (en) Treatment for alzheimer's disease
ZA971716B (en) 1,1,2-triphenylbut-1-ene derivatives for treating alzheimer's disease
AU5495398A (en) Idebenone containing combination agent for treating alzheimer's disease
ZA924128B (en) New combination preparations for treatment of Parkinson's disease.
AU114495S (en) Surgeon's hood
GB9222251D0 (en) Angler's keepnet
HU9600725D0 (en) Transdermal device containing (e)-2-(p-fluorophenethyl)-3-fluoroallylamine for the treatment of alzheimer's disease
ZA915462B (en) Composition for the treatment of alzheimer's disease and process for preparing the same
ZW17793A1 (en) "Fungicidal agents"
GB9323826D0 (en) Diagnosis of alzheimer's disease
EP0579077A3 (en) 1,3,4-thiadiazinones for the treatment of cardiovascular diseases
GB9419251D0 (en) Improved process for 4"-epi- acetylamino-4"-deoxy-5-oximinoavermectin B1
GB9024632D0 (en) Therapy for alzheimer's disease
CA70342S (en) Surgeon's hood